Currently, B2M mutation comprises point mutation, frameshift mutation, and loss of heterozygosity (LOH), which have been documented in malignant tumors like gastric cancer, colorectal cancer, renal cancer, and melanoma. The gene discussed is B2M; the disease is melanoma.